Photofrin Based Photodynamic Therapy and miR-99a Transfection Inhibited FGFR3 and PI3K/Akt Signaling Mechanisms to Control Growth of Human Glioblastoma In Vitro and In Vivo

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chakrabarti, Mrinmay ^a   Banik, Naren L ^b   Ray, Swapan K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 99A; PHOTOFRIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE OVEREXPRESSION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMET ASSAY; DIHEMATOPORPHYRIN ETHER; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOTOCHEMOTHERAPY; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84873601592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055652     Document Type: Article

References (54)

1. Dolmans DE, Fukumura D, Jain RK, (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3: 380-387.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
3. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, et al. (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193.
4. Eljamel MS, Goodman C, Moseley H, (2008) ALA and photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci 23: 361-367.
5. Eljamel S, (2010) Photodynamic applications in brain tumors: a comprehensive review of the literature. Photodiagnosis Photodyn Ther 7: 76-85.
6. Hsieh YJ, Wu CC, Chang CJ, Yu JS, (2003) Subcellular localization of photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: when plasma membranes are the main targets. J Cell Physiol 194: 363-375.
7. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO, (2009) Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 15: 4460-4466.
8. Gollnick SO, Brackett CM, (2010) Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 46: 216-226.
9. Castano AP, Mroz P, Hamblin MR, (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6: 535-545.
10. Garg AD, Nowis D, Golab J, Agostinis P, (2010) Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15: 1050-1071.
11. Silbergeld DL, Chicoine MR, (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86: 525-531.
12. Hirschberg H, Uzal FA, Chighvinadze D, Zhang MJ, Peng Q, et al. (2008) Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy. Lasers Surg Med 40: 535-542.
13. Krishnamurthy S, Powers SK, Witmer P, Brown T, (2000) Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med 27: 224-234.
14. Goodell TT, Muller PJ, (2001) Photodynamic therapy: a novel treatment for primary brain malignancy. J Neurosci Nurs 33: 296-300.
15. Zimmermann A, Ritsch-Marte M, Kostron H, (2001) mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 74: 611-616.
16. Eljamel MS, (2003) New light on the brain: the role of photosensitizing agents and laser light in the management of invasive intracranial tumors. Technol Cancer Res Treat 2: 303-309.
17. Yang VX, Muller PJ, Herman P, Wilson BC, (2003) A multispectral fluorescence imaging system: design and initial clinical tests in intra-operative photofrin-photodynamic therapy of brain tumors. Lasers Surg Med 32: 224-232.
18. Stylli SS, Howes M, MacGregor L, Rajendra P, Kaye AH, (2004) Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci 11: 584-596.
19. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355.
20. He L, Hannon GJ, (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
21. Garzon R, Calin GA, Croce CM, (2009) MicroRNAs in cancer. Annu Rev Med 60: 167-179.
22. Bonauer A, Boon RA, Dimmeler S, (2010) Vascular microRNAs. Curr Drug Targets 11: 943-949.
23. Chen Y, Gorski DH, (2008) Regulation of angiogenesis through a microRNA (miR-130a) that downregulates antiangiogenic homeobox genes GAX and HOXA5. Blood 111: 1217-1226.
24. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, et al. (2008) MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283: 15878-15883.
25. Lee DY, Deng Z, Wang CH, Yang BB, (2007) MicroRNA- 378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 104: 20350-20355.
26. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, et al. (2008) The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271.
27. Suárez Y, Fernandez-Hernando C, Pober JS, Sessa WC, (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100: 1164-1173.
28. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, et al. (2006) MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108: 3068-3071.
29. Hua Z, Lv Q, Ye W, Wong CK, Cai G, et al. (2006) miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 1: e116.
30. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949.
31. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, et al. (2010) Members of the microRNA-17-92 cluster exhibit a cellintrinsic antiangiogenic function in endothelial cells. Blood 115: 4944-4950.
32. Song G, Sharma AD, Roll GR, Ng R, Lee AY, et al. (2010) MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology 51: 1735-1743.
33. Fowler A, Thomson D, Giles K, Maleki S, Mreich E, et al. (2011) miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer 47: 953-963.
34. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: 2588-2592.
35. Mueller AC, Sun D, Dutta A (2012) The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene doi: 10.1038/onc.2012.131.
36. Marcu LG, (2010) Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain. Cancer Treat Rev 36: 606-614.
37. Collins AR, (2004) The comet assay for DNA damage and repair principles, applications, and limitations. Mol Biotechnol 26: 249-261.
38. Herrmann M, Lorenz HM, Voll R, Grünke M, Woith W, et al. (1994) A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 22: 5506-5507.
39. Griffiths-Jones S, (2004) The microRNA registry. Nucleic Acids Res 32: D109-11.
40. Jiang J, Lee EJ, Gusev Y, Schmittgen TD, (2005) Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33: 5394-5403.
41. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
42. Karmakar S, Banik NL, Ray SK, (2008) Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer 112: 596-607.
43. Engbrecht BW, Menon C, Kachur AV, Hahn SM, Fraker DL, (1999) Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res 59: 4334-4342.
44. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, et al. (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102: 12177-12182.
45. Karmakar S, Choudhury SR, Banik NL, Ray SK, (2010) Activation of multiple molecular mechanisms for increasing apoptosis in human glioblastoma T98G xenograft. J Cancer Sci Ther 2: 107-113.
46. Pawlik TM, Keyomarsi K, (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942.
47. Yu J, Zhang L, (2005) The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331: 851-858.
48. Martindale JL, Holbrook NJ, (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192: 1-15.
49. Au CM, Luk SK, Jackson CJ, Ng HK, Yow CM, et al. (2006) Differential effects of photofrin, 5-aminolevulinic acid and calphostin C on glioma cells. J Photochem Photobiol B 85: 92-101.
50. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
51. O'Gorman DM, Cotter TG, (2001) Molecular signals in anti-apoptotic survival pathways. Leukemia 15: 21-34.
52. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204.
53. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, et al. (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892.
54. Luo J, Manning BD, Cantley LC, (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262.